Infections with *Streptococcus pneumoniae* cause substantial morbidity and mortality, particularly in children in developing nations. Polysaccharide-conjugate vaccines provide protection against both invasive disease and colonization, but their use in developing countries is limited by restricted serotype coverage and expense of manufacture. Using proteomic screens, we recently identified several antigens that protected mice from pneumococcal colonization in a CD4+ T cell- and interleukin-17A (IL-17A)-dependent manner. Since several of these proteins are lipided, we hypothesized that their immunogenicity and impact on colonization are in part due to activation of Toll-like receptor 2 (TLR2), a receptor for lipoproteins. Here we show that lipided versions of the antigens elicited significantly higher activation of both human embryonic kidney cells engineered to express TLR2 (HEK-TLR2) and wild-type (WT) murine macrophages than nonlipided mutant antigens. Lipoprotein-stimulated secretion of proinflammatory cytokines was ~10× to ~100× lower in murine TLR2-deficient macrophages than in WT macrophages. Subcutaneous immunization of C57BL/6 mice with protein subunit vaccines containing one or two of these lipoproteins or protein fusion constructs bearing N-terminal lipid adducts elicited a robust IL-17A response and a significant reduction in colonization compared with immunization with alum alone. In contrast, immunization of Tlr2−/− mice elicited no detectable IL-17A response and no protection against pneumococcal colonization. These experiments suggest that the lipid moieties enhance the immunogenicity and protective efficacy of pneumococcal T17 antigens through activation of TLR2. Thus, triggering TLR2 with an antigen-specific protein subunit formulation is a possible strategy for the development of a serotype-independent pneumococcal vaccine that would reduce pneumococcal carriage.

*S. pneumoniae* is a major cause of morbidity and mortality, predominantly in young children in resource-limited settings (1). While pneumococcal conjugate vaccines (PCVs) have been highly effective at reducing invasive disease due to vaccine serotypes, limitations of this approach include emergence of disease due to nonvaccine serotypes and the high cost and complexity of PCV development and manufacture (2–4). As a result, more-affordable and serotype-independent immunization approaches are being investigated. One approach includes use of well-conserved, immunogenic, noncapsular pneumococcal antigens, either as components of a subunit protein vaccine or incorporated into PCV formulations as carrier proteins (5–7). The choice of such antigens should be informed by the evolving understanding of mechanisms of immunity to the various phases of pneumococcal infection. Several studies have demonstrated the role of interleukin-17A (IL-17A) in clearance of pneumococcal carriage in mice (8, 9). The increased incidence of pneumococcal sinopulmonary infections in patients with Job’s disease (10), now understood to be due to a genetic defect in the STAT3 transcription factor which is essential for differentiation of IL-17-producing T17 cells (11), points to the importance of this effector cytokine in humans as a mechanism of protection against mucosal pneumococcal infections.

We previously performed proteomic screens to identify a panel of antigens that were recognized by CD4+ T17 cells from mice that had been immunized with an unencapsulated killed pneumococcal whole-cell antigen (WGA) (12) and from healthy adult humans (13). Notably, several of the most immunogenic antigens identified were genetic orthologs of substrate-binding lipoproteins (LP) of ATP-binding cassette (ABC) transporter complexes. Two of these, identified by their locus within the TIGR4 sequence as SP_2108 and SP_0148, protected mice from colonization in a CD4+ T cell- and IL-17A-dependent manner when used as an intranasal vaccine (12). Given the relatively low proportion of lipoproteins within the pneumococcal proteome compared to their abundant representation within the panel of identified T17 antigens, we hypothesized that the lipid moieties of these proteins was contributing to their immunogenicity.

Several bacterial lipoproteins have been shown to activate Toll-like receptor 2 (TLR2) (14). Bacterial lipoproteins activate TLR2 early in infection, providing costimulatory signals that initiate adaptive immune responses, including TLR2-dependent antigen-presenting-cell maturation that activates naive CD4+ T cells to differentiate into effector cells (15, 16). In animal models of pneumococcal infection using TLR2 knockout mice, TLR2 has been shown to be critical for clearance in meningitis (17) and colonization (18). TLR2- and IL-17A-mediated responses have been shown to be critical for enhanced clearance of bacteria (9); in particular, a subset of pneumococcus-specific memory T17 cells...
are generated after colonization in previously exposed WT but not Tlr2−/− mice, suggesting that TLR2 activation is indeed necessary for the generation of memory CD4+ T cell responses (9).

In the present study, we tested the hypothesis that the Tlr17 immunogenicity of the two lipoproteins SP_2108 and SP_0148 is dependent on the lipid adducts signaling through TLR2. We show that the lipid modification of these proteins is critical to their immunogenicity and protective efficacy in a mouse model of pneumococcal colonization. By immunizing mice with either of these lipoproteins in combination with SP_1912, an identified Tlr17 antigen that is not lipidated (13), we also show an in trans effect of the lipoproteins that enhances the immunogenicity of the coadministered nonlipidated (Δ lipid) antigen. Furthermore, we demonstrate that multiple formulations of parenteral vaccines containing at least one of these lipoproteins confer a significant reduction in colonization in a TLR2-dependent manner. The findings described here may inform the development of next-generation protein-based vaccines for prevention of disease caused by Streptococcus pneumoniae, in particular, the mucosal phases of infection that contribute to the reservoir of transmissible pneumococci among immunized and nonimmunized individuals.

MATERIALS AND METHODS

Generation of recombinant lipoproteins, nonlipidated mutants, and fusion constructs. The SP_2108 and SP_0148 lipoproteins and nonlipidated SP_1912 (13) were cloned from strain TIGR4 S. pneumoniae DNA. To generate nonlipidated mutants of the lipoproteins, we performed site-directed mutagenesis of the cysteine residue within the conserved “lipobox” region of the lipidation sequence (19) to aspartate. The genetic fusion construct of SP_2108 and SP_1912, referred to here as fusion 2108-1912, was collinearly synthesized with the lipobox region at the N terminus. All constructs were synthesized with a C-terminal 6×His affinity tag and cloned into pET24b expression vector. Methods for expression of SP_2108 and SP_0148 lipoproteins have been previously described (19).

All proteins were purified using immobilized-metal affinity chromatography (IMAC). The lipoproteins, Δ lipid, and fusion 2108-1912 constructs were expressed as soluble proteins in Escherichia coli; SP_1912 was expressed in inclusion bodies. For the lipoprotein constructs, following microfluidization in the presence of 1% Tween 80, Lysonase (EMD Millipore), and protease inhibitors (Novagen), the proteins were captured on nickel-charged IMAC resin (GE Life Sciences), washed with sodium deoxycholate, and eluted by step gradient of imidazole. SP_1912 inclusion body pellets were resuspended in 6 M guanidine-HCl and purified in the presence of 6 M urea. Where necessary, endotoxin was removed either by precipitating purified lipoproteins with hexanediol and acetonitrile, followed by overnight incubation at 4°C, centrifugation, and drying, or by the use of ActiClean Etox columns (Cyprus International) prior to dialysis, concentration, and storage. Purified lipoproteins were dialyzed into buffer containing 10 mM Tris–HCl–10 mM NaCl (pH 8). SP_1912 was dialyzed against 2 M urea and then 5 mM sodium phosphate–5% sucrose (pH 8). Proteins were concentrated to approximately 1 mg/ml and stored at −20°C. Purified proteins were routinely analyzed for purity using 4% to 20% SDS–PAGE followed by staining with Coomassie blue and gel densitometry. Identities, as well as assessment of aggregation or degradation, were determined by Western blot analysis using protein-specific antisera. Endotoxin levels were measured by the use of an Endosafe-PTS system (Charles River). All proteins were >90% pure and contained small amounts of endotoxin. Lipidation content was determined by reverse-phase high-pressure liquid chromatography (RP-HPLC) using a C8 column (Agilent 1100). Lipidated proteins were also characterized by gas chromatography–mass spectrometry (GC-MS) and LC-MS/MS to confirm the presence of acyl chain adducts (data not shown).

Mice. For most experiments, 4- to 6-week-old C5BL/6 mice were obtained from Charles River Laboratories (C57BL/6NCrl [strain code 027]; Wilmington, MA). For experiments evaluating the role of TLR2, C57BL/6 Tlr2−/− mice (C57Bl/6-Tlr2−/− [strain code 004650]) and wild-type controls were from Jackson Laboratories (C57BL/6J [strain code 006064]; Bar Harbor, ME). Ten to 20 animals were included per immunization or control group in each experiment. All animal studies were conducted in accordance with institutional guidelines approved by the IACUC of Boston Children’s Hospital, Harvard Medical School, and Genocea Biosciences.

Immunization and immunogenicity studies. For intranasal immunizations, 4 μg of the indicated recombinant protein with 1 μg cholera toxin (CT; List Biological Laboratories Inc.) per dose was administered in a 20-μl volume in sterile phosphate-buffered saline (PBS). Animals were immunized once and then again 1 week later. For parenteral immunization, 1 to 10 μg of the indicated proteins or the fusion protein was adsorbed to 250 μg aluminum (as aluminum hydroxide [Alhydrogel; Brentnag]; referred to here as alum) per dose and administered subcutaneously in sterile saline solution in the dorsal hindquarters in 200-μl injections. Animals were immunized three times at 2-week intervals. Two to 3 weeks following the last immunization, animals were bled retro-orbitally under isoflurane anesthesia. Whole blood was stimulated with either pneumococcal WCA or the antigens of immunization as previously described (8), and the IL-17A concentration in cell supernatants was measured by enzyme-linked immunosorbent assay (ELISA) after a 6-day incubation (R&D Systems). Alternatively, 3 weeks after the last immunization, spleens were harvested and dissociated with a cell strainer into a single-cell suspension and cleared of red blood cells (ACK buffer; BioWhittaker Lonza, Walkersville, MD). Splenocytes were cultured at 200,000 cells/well and stimulated with 1 μg/ml of overlapping peptides (15-mers with 11-amino-acid overlap) spanning the vaccine antigens (IPT, Germany) in round-bottom tissue culture plates for 6 days in a final volume of 200 μl. Cell-free supernatants were collected and analyzed for IL-17A by ELISA.

Colonization. Two weeks following the bleed for immunogenicity studies, animals were challenged with an inoculum of 2 × 106 CFU of a serotype 6B pneumococcal strain in PBS. For colonization, animals were given 20 μl inocula intranasally while gently restrained and awake. Animals were sacrificed 7 days (for intranasally immunized animals) or 10 days (for parenterally immunized mice) following challenge, and nasal washes were obtained by tracheal lavage for evaluation of the density of pneumococcal colonization as previously described (20). Prior work by our group has demonstrated an effect of intranasal CT alone at diminishing pneumococcal carriage burden compared to saline solution (20). This effect of CT causes reduced carriage burden as early as 1 week after colonization challenge; thus, evaluation of nasal washes no later than 7 days postcolonization is preferred in the intranasal immunization model.

In vitro cell stimulations. HEK293 and HEK cells expressing human TLR2 (HEK-TLR2) were plated at 5 × 104 cells/well in a 96-well format or 5 × 103 cells/well in a 24-well format. One day following seeding, 1 to 0.001 μg/ml of lipoprotein, nonlipidated mutants, or Pam3CSK4 (a synthetic TLR2 agonist; InvivoGen) was added to the wells and incubated for 18 h. Supernatants were harvested, and the concentration of IL-8, a cytokine elicited by activation of HEK cells, was measured by ELISA. Similarly, 5 × 106 macrophage cells from WT or Tlr2−/− C57BL/6 mice were plated per well and were stimulated as described for the HEK cells. Supernatants and macrophage lysates were collected after 3, 6, and 24 h of stimulation and were stored at −20°C until cytokine measurements were performed. Concentrations of tumor necrosis factor alpha (TNF-α), granulocyte colony-stimulating factor (G-CSF), and IL-6 from supernatants and of IL-1β from lysates were measured by ELISA. All ELISA reagents (human IL-8 and mouse G-CSF, TNF-α, IL-6, and IL-1β) were from R&D Systems (Minneapolis, MN). Murine macrophage cell lines were kindly provided by Douglas Golenbock (University of Massachusetts Medical School), and HEK cells were from ATCC.
Statistical analyses. Data were analyzed and graphs were created in PRISM (Version 5.0d; GraphPad Software, Inc.). Significance was determined using the Mann-Whitney or Kruskal-Wallis test; \( P < 0.05 \) was considered significant. Spearman correlation coefficients were calculated with control animals excluded to avoid skewing of the strength of correlation.

RESULTS

Posttranslational attachment of lipid moieties is critical for TLR2 activation in vitro. A common mechanism whereby bacteria attach acyl groups to prolipoproteins is via the enzyme prolipoprotein diacylglycerol transferase (Lgt), which attaches a diacylglycerol moiety from phosphatidylglycerol to the cysteine residue in the N-terminal lipobox sequence of predicted lipoproteins via a thioether linkage \((19, 21)\). Additional acyl chains can be subsequently added to the amino group of cysteine (generated after signal peptide cleavage) by lipoprotein \(N\)-acyl transferase (Lnt). We identified the lipobox motif within the sequences of \(sp_{2108}\) and \(sp_{0148}\) and expressed recombinant versions of the proteins with a mutation encoding an aspartate in place of the cysteine residue on which the lipid moiety attachment occurs. RP-HPLC analysis of purified proteins confirmed the absence of acyl modification in the mutated proteins (Fig. 1A). These proteins, denoted \(\Delta\)lipid, as well as the lipidated proteins, were used to stimulate HEK cells (Fig. 1B). In these assays, native \(SP_{2108}\) and \(SP_{0148}\) lipoproteins (LP) elicited IL-8 from HEK-TLR2 cells in a dose-dependent fashion; 1 and 0.1 \(\mu\)g/ml stimulus doses elicited IL-8 secretion in the 2.6 to 3.5 ng/ml range, which was similar to the range elicited by the canonical synthetic TLR2 agonist, Pam\(_3\)CSK\(_4\). Nonlipidated mutants of \(SP_{2108}\) and \(SP_{0148}\) elicited no measurable IL-8 response in HEK TLR2 cells. No IL-8 response was detected when HEK293 cells (which do not express TLR2) were similarly stimulated with the lipidated or nonlipidated proteins (data not shown).

Nonlipidated mutants are significantly less immunogenic and less effective at reducing colonization than lipoproteins following intranasal immunization. In previous studies, \(SP_{2108}\) and \(SP_{0148}\) elicited systemic IL-17A responses when used as intranasal immunogens in a dosing schedule similar to the one described previously \((12)\). In order to evaluate the role of the lipid moieties attached to these proteins in eliciting IL-17A, we immunized mice intranasally with either the lipoproteins or their nonlipidated mutants with cholera toxin (CT) as an adjuvant. Whole blood from mice immunized with the nonlipidated mutants produced lower levels of IL-17A in response to stimulation with pneumococcal whole-cell antigen (WCA) than whole blood from mice immunized with the lipoproteins (compared to CT-immunized controls, \( P < 0.001 \) for \(SP_{2108}\), \( P < 0.05 \) for \(SP_{0148}\), and nonsignificant [NS] \( P \) for \(SP_{2108}\Delta\)lipid or \(SP_{0148}\Delta\)lipid; Fig. 2A). Similarly, while immunization with nonlipidated mutants conferred a reduction in colonization burden compared with CT immunization alone, only immunization with the lipoproteins conferred a significant reduction in carriage (\( P < 0.01 \) for...
SP_2108 and SP_0148; Fig. 2B). The burden of colonization inversely correlated with the concentration of IL-17A detected in whole-blood samples following stimulation with WCA: those animals with the highest IL-17A levels had the lowest nasal burden of pneumococci after exclusion of CT-immunized animals (Spearman coefficient, −0.46; 95% confidence interval [CI], −0.68 to −0.16; \( P = 0.003 \)). However, in this experiment the predictive relationship between IL-17A and the colonization density is not very strong, as evidenced by the fact that 8 of 10 animals in the SP_0148-immunized group were not colonized despite their whole blood producing little IL-17A when stimulated with WCA.

**SP_2108 and SP_0148 elicit Tth17-driving cytokine responses by murine macrophages in a lipid- and TLR2-dependent manner.** The results of the studies described above supported the hypothesis that the lipid motifs in SP_2108 and SP_0148 may be responsible for driving Tth17 responses in mice. To assess this possibility further, we examined the cytokine response following stimulation of antigen-presenting cells. The recombinant lipoproteins and nonlipidated mutants were used to stimulate macrophages from WT and Tlr2−/− C57BL/6 mice. Cell supernatants were assayed for concentrations of TNF-\( \alpha \), all proinflammatory cytokines that either promote development of adaptive TH17 cell differentiation (22, 23) or act synergistically with IL-17A (24). While IL-17A has been shown to be produced by some innate immune cells (24), there was no detectable IL-17A in these supernatants.

Stimulation of WT macrophages with SP_2108 and SP_0148 lipoproteins led to an IL-6 and IL-1-\( \beta \) response similar in magnitude and kinetics to those seen following stimulation with Pam3CSK4 (Fig. 3A and C). In contrast, responses following stimulation with nonlipidated versions of the proteins were virtually undetectable. Tlr2−/− macrophages did not respond following stimulation with lipoproteins, indicating that the observed response was TLR2 dependent. The lipoproteins and Pam3CSK4 also stimulated TNF-\( \alpha \) and G-CSF responses in a TLR2-dependent manner (Fig. 3B and D). IL-23 was not detectable. Concentrations of TGF-\( \beta \) were elevated under all stimulation conditions, including in medium-only control wells, and thus were not evaluable. Nonlipidated SP_0148 did elicit IL-6, TNF-\( \alpha \), and G-CSF responses in a TLR2-independent manner, perhaps suggesting different innate stimulatory properties of this protein. Heating recombinant SP_0148 lipid to 100°C for 1 h did abrogate its proinflammatory effect (data not shown), suggesting that lipopolysaccharide contamination was an unlikely cause.

**Immunogenicity and protective efficacy of parenterally administered lipoproteins.** Next, we examined whether Tth17 responses to the lipoproteins could be elicited by immunizing animals parenterally without the use of CT, an adjuvant known to skew responses along the IL-17A axis (25, 26). We first confirmed the critical role of the lipid moiety in eliciting IL-17A following subcutaneous immunization with SP_2108 and SP_0148, each adsorbed onto alum. Indeed, subcutaneous immunization with the lipidated proteins conferred demonstrable IL-17A responses measured from splenocytes cultured with immunogen-specific stimuli, whereas no IL-17A was detected following immunization with nonlipidated mutants (see Fig. S1 in the supplemental material).

Next, with the goal of expanding the coverage of a protein subunit vaccine, we looked to the results of our proteomic screen using human blood samples (13), from which we had identified SP_1912, a nonlipidated protein of unknown function that conferred significant protection when administered intranasally using CT as an adjuvant (data not shown). We immunized WT mice subcutaneously three times at 2-week intervals with a mixture of SP_2108, SP_0148, and SP_1912 adsorbed onto alum. As shown...
in Fig. 4A, pneumococcus-specific IL-17A responses could be readily measured following immunization with the mixture of proteins. Interestingly, in similar immunization regimens, a T_{H}17 response to SP_1912 could be detected after immunization with the mixture containing the lipoproteins but not when SP_1912 was used as a single immunogen (\( P = 0.0008 \) comparing IL-17A conferred by SP_1912 immunization alone to immunization with the lipoprotein-containing mixture; see Fig. S2A in the supplemental material). Based on these results and to reduce the number of constructs in the vaccine, we made a fusion construct of SP_2108 with SP_1912 which contains the lipid moiety of SP_2108. As shown in Fig. S3, this construct has potent TLR2-stimulating activity. Mice immunized with the genetic fusion of these two proteins developed pneumococcus-specific IL-17A responses.
The density of pneumococcal colonization was determined 10 days following intranasal challenge with live pneumococci. Compared to mice that received alum alone, mice immunized with the mixture of proteins or the fusion construct had a significant reduction in the density of pneumococcal carriage \( (P = 0.0008 \text{ or } P < 0.0001, \text{ respectively); Fig. 4B}. \)

The immunogenicity and efficacy of the lipoproteins are TLR2 dependent. In contrast to WT mice, \( \text{Thr}^{2-/-} \) mice immunized with either the mixture of the three proteins or the fusion construct did not generate detectable IL-17A responses \( (P = 0.0002 \text{ or } P = 0.0002 \text{ comparing the WT mice to } \text{Thr}^{2-/-} \text{ mice within each immunization group, respectively; Fig. 4A}. \). Interestingly, the in trans effect, whereby \( \text{T}_{\text{h}}17 \) responses to SP_1912 were elicited by coadministration or fusion with lipoproteins, was also found to be TLR2 dependent (see Fig. S2B in the supplemental material). Furthermore, unlike in WT mice, immunization with either the mixture of SP_2108, SP_0148, and SP_1912 or the fusion of SP_2108 and SP_1912 conferred no reduction in pneumococcal colonization density in \( \text{Thr}^{2-/-} \) mice \( (P = 0.005 \text{ or } P = 0.0001 \text{ comparing WT to } \text{Thr}^{2-/-} \text{ mice within each immunization group, respectively; Fig. 4B}. \). Importantly, alum-immunized WT and \( \text{Thr}^{2-/-} \) mice showed similar densities of colonization, suggesting that the lack of protection in immunized \( \text{Thr}^{2-/-} \text{ mice is not due to an inherent increased susceptibility to pneumococcal carriage due to the lack of TLR2}. \)

**DISCUSSION**

Over the past several decades, there have been many efforts, both preclinical and clinical, to develop a serotype-independent pneumococcal vaccine, primarily with the goal to elicit protective antibodies to conserved proteins \( (5, 7, 27) \). With the recent discovery of T cell-mediated resistance to pneumococcal colonization in mice \( (28, 29) \), it has been proposed that a protein-based vaccine should incorporate antigens that confer both antibody- and T cell-based protection against pneumococcal disease and carriage. In this work, we explored the role of the lipid moieties of two highly immunogenic \( \text{T}_{\text{h}}17 \) antigens previously identified by proteomic screens, SP_2108 and SP_0148, focusing on the possible role of TLR2 activation in protection against colonization.

Our understanding of the role of IL-17A-mediated immune responses to mucosal infection has expanded over the last several years, as more evidence of their importance in the defense against extracellular bacterial infections has become available \( (30, 31) \). Subsequently, a critical role of TLR2 in the generation of protective IL-17A immune responses to mucosal infections by *Salmonella enterica* serovar Typhimurium and *Yersinia enterocolitica* was demonstrated \( (32, 33) \). A requirement for TLR2 for the development of systemic pneumococcus-specific CD4+ IL-17A-secreting cells following primary pneumococcal colonization was recently demonstrated \( (9) \). Here we evaluated the role of TLR2 in the development of vaccine-induced IL-17A immune responses using two pneumococcal lipoproteins as immunogens that induce \( \text{T}_{\text{h}}17 \) responses. Our studies show that attachment of lipid moieties is required for optimal immunogenicity of SP_2108 and SP_0148 and that this immunogenicity is TLR2 dependent. Active immunization studies using the lipoproteins as components of either mucosal or parenteral vaccines confirmed that both the lipid moieties and TLR2 enhance IL-17A immunogenicity and resistance to pneumococcal colonization following immunization.

Our findings in intranasal immunization experiments using either of the two lipoproteins or their nonlipidated counterparts alone demonstrated that, even in the presence of the potent \( \text{T}_{\text{h}}17 \)-driving adjuvant CT \( (25, 26) \), the lipid moieties enhance responses \( (\text{Fig. 2B}). \) The critical role of the lipid moieties in enhancing the IL-17A immunogenicity of SP_2108 and SP_0148 was further demonstrated in parenteral immunization experiments using alum as an adjuvant (see Fig. S1 in the supplemental material). In vitro responses from WT and \( \text{Thr}^{2-/-} \) macrophages demonstrated that the proinflammatory properties of these proteins are TLR2 dependent. Recent studies have suggested that dendritic cells are the primary antigen-presenting cells driving mucosal \( \text{T}_{\text{h}}17 \) cell differentiation \( \text{in vivo} \) \( (34, 35) \). As such, evaluation of the immunogenicity of such proteins using dendritic cell lines should be considered.

We also demonstrated some differences in the immunogenicity and proinflammatory properties of SP_2108 and SP_0148. For example, in contrast to SP_2108 results, lipidation of SP_0148 did not significantly enhance the IL-17A responses to this antigen when given intranasally with CT (Fig. 2A). However, there was a much more robust increase in IL-17A responses to SP_0148 given subcutaneously with alum than to the nonlipidated protein (see Fig. S1 in the supplemental material). This might suggest that the mechanisms by which lipid moieties act as an adjuvant to the immunogenicity of a protein are dependent on many factors, including the route of immunization and characteristics of the protein itself such as the presence of particular T cell epitopes. Indeed, we note a weak correlation between SP_0148-elicited IL-17A responses and colonization burden following intranasal immunization. Beyond the possibility that protein-elicited systemic IL-17A responses are simply not very good predictors of protection against carriage in mice (unlike the case of the whole-cell pneumococcal vaccine, where the correlation is much stronger \( (8) \)), one can also speculate that immune mechanisms other than IL-17A may contribute to SP_0148 (and possibly other protein)-mediated clearance of pneumococcal carriage. Such mechanisms could include other T cell-derived cytokines such as IL-22 \( (36, 37) \), antibody-mediated clearance, or a combination of immune effectors. There is also the suggestion from in vitro studies that SP_0148 may have TLR2-independent proinflammatory properties, as seen following stimulation with the nonlipidated mutant (Fig. 3). Since this effect was abrogated following stimulation with a boiled SP_0148 lipopreparation, it is less likely to be the result of lipopolysaccharide (LPS) contamination, but the mechanism for this stimulatory effect remains to be explained. In considering inclusion of pneumococcal proteins in next-generation vaccines, the use of proteins that are immunogens and also confer lipid-mediated \( \text{T}_{\text{h}}17 \)-promoting effects might be optimal.

Activation of TLRs expressed on macrophages and dendritic cells leads to a cascade of innate immune events, including proinflammatory cytokine release and upregulation of major histocompatibility complex (MHC) molecules and costimulatory signals, resulting in enhancement of adaptive immune responses \( (38) \). Here we show that the TLR2- and lipid-mediated adjuvant effect appears to work in trans, since the \( \text{T}_{\text{h}}17 \) responses to SP_1912, a nonlipidated protein, could be elicited by coadministration with the two lipoproteins. Another approach is to create fusion proteins, including a lipid motif, as shown here with the fusion of...
SP_2108 and SP_1912. Such enhancement of immunogenicity and protection against pneumococcal colonization by fusion of proteins had been previously demonstrated with pneumolysin, a TLR4 agonist (39–41). Here we show this with a TLR2 agonist fused to the antigenic cargo, which likely enhances MHC class II (MHC-II) presentation (42).

Beyond the potential to confer serotype-independent immunity to pneumococcus, the inclusion of TLR2-activating proteins in a conjugate vaccine, either as a mixture or as carrier proteins, may enhance the immune responses to the polysaccharides. Of the three Haemophilus influenzae type B (Hib) polysaccharide conjugate vaccines that have been licensed, one uses a meningoococcal outer membrane protein complex as the Hib polysaccharide carrier (Hib-OMPC) and was noted to be more immunogenic after 1 dose in infants than Hib conjugates that included either CRM197 or tetanus toxoid as carriers (43). A possible explanation for these findings was that the Hib-OMPC vaccine, unlike the other licensed Hib conjugate vaccines, activates TLR2 and that enhanced polysaccharide responses observed in mice were TLR2 dependent (44). Whether the inclusion of TLR2-activating proteins in a pneumococcal polysaccharide conjugate vaccine would similarly enhance the potency of pneumococcal polysaccharide-directed immunity deserves further investigation.

By extension, our data regarding the role of lipids and TLR2, as well as the in trans effect we noted, also suggest a possible strategy to develop vaccines directed against other mucosal pathogens for which a role of TLR17 has been demonstrated, for example, Staphylococcus aureus (45), Bordetella pertussis (46), and Mycobacterium tuberculosis (47). The selection of naturally lipidated TLR17 antigens from these organisms, lipidation of candidate antigens, and the inclusion of a TLR2-activating adjuvant in the formulation could all be considered in the design of a novel vaccine directed against these mucosal pathogens.

In conclusion, we demonstrate that the immunogenicity and the protective efficacy against pneumococcal colonization that is elicited following immunization with TLR17 lipoproteins are dependent on their attached lipid moieties and are mediated by TLR2. These lipoproteins also enhance the immunogenicity of nonlipidated proteins included in the same vaccines. Based on their immunogenic and adjuvant properties, inclusion of these and similarly lipidated pneumococcal antigens as components of next-generation pneumococcal vaccines is worthy of further exploration. To this end, a phase 1 clinical trial of proteins described in this work is under way (ClinicalTrials.gov identifier NCT01995617).

ACKNOWLEDGMENTS

We gratefully acknowledge PATH for supporting these studies. Further funding for this work was provided by NIH grant K08 AI095352 (K.M.). R.M. acknowledges support from the Translational Research Program at Boston Children’s Hospital. M.S., L.C.G., S.M., B.D., P.G., and J.B.F. are employees of Genoceca Biosciences, Inc. T.G. is a former employee of and owns stock in Genoceca Biosciences, Inc.

REFERENCES


18. van Rossum AM, Lysenko ES, Weiser JN. 2005. Host and bacterial


